Part 2/8:
Rapamycin, initially identified in the 1960s during an expedition to Easter Island, originates from a soil sample containing a bacterium with potent antifungal properties. Initially envisioned as a treatment for fungal infections, further investigation revealed rapamycin's powerful immunosuppressive capabilities. In 1999, the FDA approved it for organ transplant patients to prevent the rejection of transplanted organs due to immune system response.